nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Topoisomerase Inhibitors—Etoposide—muscle cancer	0.382	1	CiPCiCtD
Doxorubicin—hematologic cancer—muscle cancer	0.0531	0.165	CtDrD
Doxorubicin—uterine cancer—muscle cancer	0.0435	0.135	CtDrD
Doxorubicin—urinary bladder cancer—muscle cancer	0.0407	0.127	CtDrD
Doxorubicin—bone cancer—muscle cancer	0.039	0.121	CtDrD
Doxorubicin—RALBP1—Vincristine—muscle cancer	0.0374	0.179	CbGbCtD
Doxorubicin—testicular cancer—muscle cancer	0.0323	0.101	CtDrD
Doxorubicin—ABCC6—Dactinomycin—muscle cancer	0.0292	0.14	CbGbCtD
Doxorubicin—kidney cancer—muscle cancer	0.0288	0.0898	CtDrD
Doxorubicin—peripheral nervous system neoplasm—muscle cancer	0.0286	0.0889	CtDrD
Doxorubicin—lung cancer—muscle cancer	0.0278	0.0866	CtDrD
Doxorubicin—sarcoma—muscle cancer	0.0275	0.0856	CtDrD
Doxorubicin—ABCC6—Etoposide—muscle cancer	0.0165	0.0788	CbGbCtD
Doxorubicin—ABCC10—Vincristine—muscle cancer	0.0137	0.0657	CbGbCtD
Doxorubicin—ABCC10—Etoposide—muscle cancer	0.0126	0.0602	CbGbCtD
Doxorubicin—TOP2A—Etoposide—muscle cancer	0.00877	0.0419	CbGbCtD
Doxorubicin—ABCC3—Vincristine—muscle cancer	0.00864	0.0413	CbGbCtD
Doxorubicin—ABCC1—Dactinomycin—muscle cancer	0.00861	0.0412	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—muscle cancer	0.00832	0.0398	CbGbCtD
Doxorubicin—ABCC3—Etoposide—muscle cancer	0.00792	0.0378	CbGbCtD
Doxorubicin—ABCB11—Vincristine—muscle cancer	0.00747	0.0357	CbGbCtD
Doxorubicin—ABCG2—Dactinomycin—muscle cancer	0.00576	0.0276	CbGbCtD
Doxorubicin—ABCC1—Vincristine—muscle cancer	0.0053	0.0254	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—muscle cancer	0.00523	0.025	CbGbCtD
Doxorubicin—ABCC1—Etoposide—muscle cancer	0.00486	0.0232	CbGbCtD
Doxorubicin—ABCC2—Vincristine—muscle cancer	0.00393	0.0188	CbGbCtD
Doxorubicin—ABCC2—Etoposide—muscle cancer	0.0036	0.0172	CbGbCtD
Doxorubicin—ABCG2—Vincristine—muscle cancer	0.00355	0.017	CbGbCtD
Doxorubicin—ABCG2—Etoposide—muscle cancer	0.00325	0.0155	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—muscle cancer	0.00321	0.0154	CbGbCtD
Doxorubicin—ABCC2—Methotrexate—muscle cancer	0.00238	0.0114	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—muscle cancer	0.00215	0.0103	CbGbCtD
Doxorubicin—ABCB1—Dactinomycin—muscle cancer	0.00208	0.00994	CbGbCtD
Doxorubicin—ABCB1—Vincristine—muscle cancer	0.00128	0.00612	CbGbCtD
Doxorubicin—ABCB1—Etoposide—muscle cancer	0.00117	0.00561	CbGbCtD
Doxorubicin—NOS3—hindlimb—muscle cancer	0.000857	0.0324	CbGeAlD
Doxorubicin—ABCB1—Methotrexate—muscle cancer	0.000775	0.0037	CbGbCtD
Doxorubicin—CYP3A4—Vincristine—muscle cancer	0.000767	0.00367	CbGbCtD
Doxorubicin—NOS3—appendage—muscle cancer	0.000735	0.0278	CbGeAlD
Doxorubicin—CYP3A4—Etoposide—muscle cancer	0.000703	0.00336	CbGbCtD
Doxorubicin—SLC22A16—renal system—muscle cancer	0.000555	0.021	CbGeAlD
Doxorubicin—CBR3—embryo—muscle cancer	0.000549	0.0208	CbGeAlD
Doxorubicin—NOS2—tendon—muscle cancer	0.000523	0.0198	CbGeAlD
Doxorubicin—ABCB8—renal system—muscle cancer	0.000432	0.0163	CbGeAlD
Doxorubicin—SLC22A16—bone marrow—muscle cancer	0.00042	0.0159	CbGeAlD
Doxorubicin—SLC22A16—testis—muscle cancer	0.000359	0.0136	CbGeAlD
Doxorubicin—AKR1A1—smooth muscle tissue—muscle cancer	0.000333	0.0126	CbGeAlD
Doxorubicin—CBR3—tendon—muscle cancer	0.000324	0.0123	CbGeAlD
Doxorubicin—AKR1A1—renal system—muscle cancer	0.000321	0.0121	CbGeAlD
Doxorubicin—CBR3—vagina—muscle cancer	0.000301	0.0114	CbGeAlD
Doxorubicin—NDUFS7—renal system—muscle cancer	0.000292	0.011	CbGeAlD
Doxorubicin—ABCB8—head—muscle cancer	0.000289	0.0109	CbGeAlD
Doxorubicin—AKR1A1—cardiac atrium—muscle cancer	0.000287	0.0109	CbGeAlD
Doxorubicin—ABCB8—testis—muscle cancer	0.000279	0.0106	CbGeAlD
Doxorubicin—CBR3—head—muscle cancer	0.000278	0.0105	CbGeAlD
Doxorubicin—AURKA—renal system—muscle cancer	0.000271	0.0103	CbGeAlD
Doxorubicin—CBR3—testis—muscle cancer	0.000269	0.0102	CbGeAlD
Doxorubicin—NDUFS7—cardiac atrium—muscle cancer	0.000261	0.00988	CbGeAlD
Doxorubicin—NOS1—smooth muscle tissue—muscle cancer	0.000253	0.00956	CbGeAlD
Doxorubicin—NDUFS2—smooth muscle tissue—muscle cancer	0.000251	0.0095	CbGeAlD
Doxorubicin—AKR1A1—tendon—muscle cancer	0.00025	0.00948	CbGeAlD
Doxorubicin—NDUFS3—smooth muscle tissue—muscle cancer	0.000248	0.00938	CbGeAlD
Doxorubicin—ABCC6—Podofilox—Etoposide—muscle cancer	0.000247	0.208	CbGdCrCtD
Doxorubicin—NOS1—renal system—muscle cancer	0.000243	0.0092	CbGeAlD
Doxorubicin—AKR1A1—bone marrow—muscle cancer	0.000243	0.00918	CbGeAlD
Doxorubicin—NDUFS2—renal system—muscle cancer	0.000242	0.00914	CbGeAlD
Doxorubicin—NDUFS3—renal system—muscle cancer	0.000239	0.00903	CbGeAlD
Doxorubicin—AKR1A1—vagina—muscle cancer	0.000232	0.00879	CbGeAlD
Doxorubicin—NDUFS7—tendon—muscle cancer	0.000228	0.00861	CbGeAlD
Doxorubicin—CBR3—Teniposide—Etoposide—muscle cancer	0.000222	0.187	CbGdCrCtD
Doxorubicin—ABCC6—renal system—muscle cancer	0.000221	0.00836	CbGeAlD
Doxorubicin—NDUFS7—bone marrow—muscle cancer	0.00022	0.00834	CbGeAlD
Doxorubicin—NDUFS2—cardiac atrium—muscle cancer	0.000216	0.00819	CbGeAlD
Doxorubicin—YWHAG—smooth muscle tissue—muscle cancer	0.000216	0.00818	CbGeAlD
Doxorubicin—AKR1C3—Podofilox—Etoposide—muscle cancer	0.000216	0.182	CbGdCrCtD
Doxorubicin—AKR1A1—head—muscle cancer	0.000215	0.00812	CbGeAlD
Doxorubicin—NDUFS3—cardiac atrium—muscle cancer	0.000214	0.00809	CbGeAlD
Doxorubicin—AURKA—tendon—muscle cancer	0.000212	0.00801	CbGeAlD
Doxorubicin—NDUFS7—vagina—muscle cancer	0.000211	0.00799	CbGeAlD
Doxorubicin—YWHAG—renal system—muscle cancer	0.000208	0.00787	CbGeAlD
Doxorubicin—AKR1A1—testis—muscle cancer	0.000207	0.00785	CbGeAlD
Doxorubicin—AURKA—bone marrow—muscle cancer	0.000205	0.00776	CbGeAlD
Doxorubicin—DHCR7—cardiac atrium—muscle cancer	0.000203	0.00768	CbGeAlD
Doxorubicin—XDH—renal system—muscle cancer	0.000203	0.00768	CbGeAlD
Doxorubicin—AURKA—vagina—muscle cancer	0.000196	0.00743	CbGeAlD
Doxorubicin—RALBP1—smooth muscle tissue—muscle cancer	0.000195	0.00739	CbGeAlD
Doxorubicin—NDUFS7—head—muscle cancer	0.000195	0.00738	CbGeAlD
Doxorubicin—NOS3—smooth muscle tissue—muscle cancer	0.000192	0.00727	CbGeAlD
Doxorubicin—NOS1—tendon—muscle cancer	0.00019	0.00718	CbGeAlD
Doxorubicin—NDUFS2—tendon—muscle cancer	0.000189	0.00714	CbGeAlD
Doxorubicin—NDUFS7—testis—muscle cancer	0.000188	0.00713	CbGeAlD
Doxorubicin—RALBP1—renal system—muscle cancer	0.000188	0.00711	CbGeAlD
Doxorubicin—YWHAG—cardiac atrium—muscle cancer	0.000186	0.00705	CbGeAlD
Doxorubicin—NDUFS3—tendon—muscle cancer	0.000186	0.00705	CbGeAlD
Doxorubicin—NOS3—renal system—muscle cancer	0.000185	0.00699	CbGeAlD
Doxorubicin—NDUFS2—bone marrow—muscle cancer	0.000183	0.00691	CbGeAlD
Doxorubicin—AURKA—head—muscle cancer	0.000181	0.00686	CbGeAlD
Doxorubicin—NDUFS3—bone marrow—muscle cancer	0.00018	0.00683	CbGeAlD
Doxorubicin—AKR1C3—smooth muscle tissue—muscle cancer	0.00018	0.00681	CbGeAlD
Doxorubicin—CBR1—renal system—muscle cancer	0.000175	0.00664	CbGeAlD
Doxorubicin—AURKA—testis—muscle cancer	0.000175	0.00663	CbGeAlD
Doxorubicin—NDUFS2—vagina—muscle cancer	0.000175	0.00662	CbGeAlD
Doxorubicin—NDUFS3—vagina—muscle cancer	0.000173	0.00654	CbGeAlD
Doxorubicin—DHCR7—bone marrow—muscle cancer	0.000171	0.00649	CbGeAlD
Doxorubicin—RALBP1—cardiac atrium—muscle cancer	0.000168	0.00637	CbGeAlD
Doxorubicin—DHCR7—vagina—muscle cancer	0.000164	0.00621	CbGeAlD
Doxorubicin—NOS1—head—muscle cancer	0.000163	0.00616	CbGeAlD
Doxorubicin—YWHAG—tendon—muscle cancer	0.000162	0.00615	CbGeAlD
Doxorubicin—NDUFS2—head—muscle cancer	0.000162	0.00612	CbGeAlD
Doxorubicin—NDUFS3—head—muscle cancer	0.00016	0.00604	CbGeAlD
Doxorubicin—YWHAG—bone marrow—muscle cancer	0.000157	0.00595	CbGeAlD
Doxorubicin—NOS1—testis—muscle cancer	0.000157	0.00595	CbGeAlD
Doxorubicin—CBR1—cardiac atrium—muscle cancer	0.000157	0.00594	CbGeAlD
Doxorubicin—NDUFS2—testis—muscle cancer	0.000156	0.00591	CbGeAlD
Doxorubicin—AKR1C3—cardiac atrium—muscle cancer	0.000155	0.00587	CbGeAlD
Doxorubicin—NDUFS3—testis—muscle cancer	0.000154	0.00584	CbGeAlD
Doxorubicin—DHCR7—head—muscle cancer	0.000152	0.00574	CbGeAlD
Doxorubicin—YWHAG—vagina—muscle cancer	0.000151	0.0057	CbGeAlD
Doxorubicin—AKR1C3—Vinblastine—Vincristine—muscle cancer	0.000148	0.125	CbGdCrCtD
Doxorubicin—ABCC6—head—muscle cancer	0.000148	0.00559	CbGeAlD
Doxorubicin—XDH—vagina—muscle cancer	0.000147	0.00556	CbGeAlD
Doxorubicin—RALBP1—tendon—muscle cancer	0.000147	0.00555	CbGeAlD
Doxorubicin—DHCR7—testis—muscle cancer	0.000147	0.00555	CbGeAlD
Doxorubicin—NQO1—smooth muscle tissue—muscle cancer	0.000146	0.00552	CbGeAlD
Doxorubicin—NOS3—tendon—muscle cancer	0.000144	0.00546	CbGeAlD
Doxorubicin—RALBP1—bone marrow—muscle cancer	0.000142	0.00538	CbGeAlD
Doxorubicin—POR—cardiac atrium—muscle cancer	0.000142	0.00536	CbGeAlD
Doxorubicin—NQO1—renal system—muscle cancer	0.000141	0.00532	CbGeAlD
Doxorubicin—YWHAG—head—muscle cancer	0.000139	0.00527	CbGeAlD
Doxorubicin—CBR1—tendon—muscle cancer	0.000137	0.00518	CbGeAlD
Doxorubicin—RALBP1—vagina—muscle cancer	0.000136	0.00515	CbGeAlD
Doxorubicin—AKR1C3—tendon—muscle cancer	0.000135	0.00512	CbGeAlD
Doxorubicin—YWHAG—testis—muscle cancer	0.000134	0.00509	CbGeAlD
Doxorubicin—NOS3—vagina—muscle cancer	0.000134	0.00507	CbGeAlD
Doxorubicin—CBR1—bone marrow—muscle cancer	0.000133	0.00502	CbGeAlD
Doxorubicin—AKR1C3—bone marrow—muscle cancer	0.000131	0.00496	CbGeAlD
Doxorubicin—ABCB11—testis—muscle cancer	0.000128	0.00485	CbGeAlD
Doxorubicin—CBR1—vagina—muscle cancer	0.000127	0.00481	CbGeAlD
Doxorubicin—ABCC3—renal system—muscle cancer	0.000126	0.00477	CbGeAlD
Doxorubicin—RALBP1—head—muscle cancer	0.000126	0.00476	CbGeAlD
Doxorubicin—ABCC10—renal system—muscle cancer	0.000125	0.00475	CbGeAlD
Doxorubicin—AKR1C3—vagina—muscle cancer	0.000125	0.00475	CbGeAlD
Doxorubicin—NOS3—head—muscle cancer	0.000124	0.00468	CbGeAlD
Doxorubicin—POR—tendon—muscle cancer	0.000123	0.00467	CbGeAlD
Doxorubicin—RALBP1—testis—muscle cancer	0.000121	0.0046	CbGeAlD
Doxorubicin—POR—bone marrow—muscle cancer	0.00012	0.00453	CbGeAlD
Doxorubicin—NOS3—testis—muscle cancer	0.000119	0.00452	CbGeAlD
Doxorubicin—CBR1—head—muscle cancer	0.000117	0.00444	CbGeAlD
Doxorubicin—AURKA—Teniposide—Etoposide—muscle cancer	0.000117	0.0987	CbGdCrCtD
Doxorubicin—TOP2A—tendon—muscle cancer	0.000115	0.00435	CbGeAlD
Doxorubicin—POR—vagina—muscle cancer	0.000115	0.00434	CbGeAlD
Doxorubicin—CBR1—testis—muscle cancer	0.000113	0.00429	CbGeAlD
Doxorubicin—ABCC10—cardiac atrium—muscle cancer	0.000112	0.00425	CbGeAlD
Doxorubicin—AKR1C3—testis—muscle cancer	0.000112	0.00424	CbGeAlD
Doxorubicin—TOP2A—bone marrow—muscle cancer	0.000111	0.00422	CbGeAlD
Doxorubicin—NQO1—tendon—muscle cancer	0.00011	0.00415	CbGeAlD
Doxorubicin—TOP2A—vagina—muscle cancer	0.000107	0.00404	CbGeAlD
Doxorubicin—CYP1B1—smooth muscle tissue—muscle cancer	0.000103	0.00388	CbGeAlD
Doxorubicin—POR—testis—muscle cancer	0.000102	0.00387	CbGeAlD
Doxorubicin—NQO1—vagina—muscle cancer	0.000102	0.00385	CbGeAlD
Doxorubicin—ABCC2—renal system—muscle cancer	0.000101	0.00381	CbGeAlD
Doxorubicin—CYP1B1—renal system—muscle cancer	9.87e-05	0.00373	CbGeAlD
Doxorubicin—ABCC10—tendon—muscle cancer	9.8e-05	0.00371	CbGeAlD
Doxorubicin—TOP2A—testis—muscle cancer	9.53e-05	0.00361	CbGeAlD
Doxorubicin—ABCC10—bone marrow—muscle cancer	9.49e-05	0.00359	CbGeAlD
Doxorubicin—NQO1—head—muscle cancer	9.4e-05	0.00356	CbGeAlD
Doxorubicin—ABCC10—vagina—muscle cancer	9.09e-05	0.00344	CbGeAlD
Doxorubicin—NQO1—testis—muscle cancer	9.08e-05	0.00344	CbGeAlD
Doxorubicin—ABCC3—head—muscle cancer	8.44e-05	0.00319	CbGeAlD
Doxorubicin—ABCC3—testis—muscle cancer	8.15e-05	0.00308	CbGeAlD
Doxorubicin—ABCC10—testis—muscle cancer	8.11e-05	0.00307	CbGeAlD
Doxorubicin—ABCC1—cardiac atrium—muscle cancer	7.95e-05	0.00301	CbGeAlD
Doxorubicin—ABCC2—tendon—muscle cancer	7.87e-05	0.00298	CbGeAlD
Doxorubicin—CYP1B1—tendon—muscle cancer	7.7e-05	0.00292	CbGeAlD
Doxorubicin—TOP2A—Vindesine—Vincristine—muscle cancer	7.09e-05	0.0598	CbGdCrCtD
Doxorubicin—ABCC1—tendon—muscle cancer	6.93e-05	0.00262	CbGeAlD
Doxorubicin—CYP2B6—renal system—muscle cancer	6.78e-05	0.00257	CbGeAlD
Doxorubicin—CYP1B1—head—muscle cancer	6.6e-05	0.0025	CbGeAlD
Doxorubicin—ABCC2—testis—muscle cancer	6.51e-05	0.00246	CbGeAlD
Doxorubicin—ABCC1—vagina—muscle cancer	6.43e-05	0.00243	CbGeAlD
Doxorubicin—CYP1B1—testis—muscle cancer	6.38e-05	0.00241	CbGeAlD
Doxorubicin—AURKA—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	6.16e-05	0.00254	CbGpPWpGaD
Doxorubicin—ABCC1—testis—muscle cancer	5.74e-05	0.00217	CbGeAlD
Doxorubicin—ABCC1—S1P1 pathway—VEGFA—muscle cancer	5.72e-05	0.00236	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—ANGPT2—muscle cancer	5.69e-05	0.00235	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	5.68e-05	0.00234	CbGpPWpGaD
Doxorubicin—NOS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	5.61e-05	0.00231	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.58e-05	0.0023	CbGpPWpGaD
Doxorubicin—ABCG2—bone marrow—muscle cancer	5.56e-05	0.0021	CbGeAlD
Doxorubicin—NDUFS3—Metabolism—FH—muscle cancer	5.5e-05	0.00227	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—FH—muscle cancer	5.5e-05	0.00227	CbGpPWpGaD
Doxorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	5.44e-05	0.00224	CbGpPWpGaD
Doxorubicin—CYP2B6—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	5.34e-05	0.0022	CbGpPWpGaD
Doxorubicin—ABCG2—vagina—muscle cancer	5.32e-05	0.00201	CbGeAlD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	5.3e-05	0.00219	CbGpPWpGaD
Doxorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	5.28e-05	0.00218	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.2e-05	0.00214	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—FH—muscle cancer	5.17e-05	0.00213	CbGpPWpGaD
Doxorubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—muscle cancer	5.13e-05	0.00212	CbGpPWpGaD
Doxorubicin—CYP3A4—renal system—muscle cancer	5.12e-05	0.00194	CbGeAlD
Doxorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	5.08e-05	0.0021	CbGpPWpGaD
Doxorubicin—CYP2D6—renal system—muscle cancer	5.04e-05	0.00191	CbGeAlD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	5.03e-05	0.00207	CbGpPWpGaD
Doxorubicin—CYP2B6—vagina—muscle cancer	4.91e-05	0.00186	CbGeAlD
Doxorubicin—ABCB1—embryo—muscle cancer	4.79e-05	0.00181	CbGeAlD
Doxorubicin—ABCG2—testis—muscle cancer	4.75e-05	0.0018	CbGeAlD
Doxorubicin—Cystitis—Methotrexate—muscle cancer	4.74e-05	0.00134	CcSEcCtD
Doxorubicin—NOS1—Spinal Cord Injury—PTGS2—muscle cancer	4.72e-05	0.00195	CbGpPWpGaD
Doxorubicin—Cardiac disorder—Vincristine—muscle cancer	4.72e-05	0.00133	CcSEcCtD
Doxorubicin—Skin exfoliation—Methotrexate—muscle cancer	4.69e-05	0.00132	CcSEcCtD
Doxorubicin—YWHAG—LKB1 signaling events—TP53—muscle cancer	4.65e-05	0.00192	CbGpPWpGaD
Doxorubicin—Vaginal infection—Methotrexate—muscle cancer	4.63e-05	0.00131	CcSEcCtD
Doxorubicin—Pneumonia—Etoposide—muscle cancer	4.61e-05	0.0013	CcSEcCtD
Doxorubicin—Angiopathy—Vincristine—muscle cancer	4.61e-05	0.0013	CcSEcCtD
Doxorubicin—Aplastic anaemia—Methotrexate—muscle cancer	4.61e-05	0.0013	CcSEcCtD
Doxorubicin—Ill-defined disorder—Dactinomycin—muscle cancer	4.59e-05	0.0013	CcSEcCtD
Doxorubicin—Infestation—Etoposide—muscle cancer	4.58e-05	0.00129	CcSEcCtD
Doxorubicin—Infestation NOS—Etoposide—muscle cancer	4.58e-05	0.00129	CcSEcCtD
Doxorubicin—Mediastinal disorder—Vincristine—muscle cancer	4.58e-05	0.00129	CcSEcCtD
Doxorubicin—Anaemia—Dactinomycin—muscle cancer	4.58e-05	0.00129	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Etoposide—muscle cancer	4.55e-05	0.00128	CcSEcCtD
Doxorubicin—CYP2B6—head—muscle cancer	4.54e-05	0.00172	CbGeAlD
Doxorubicin—Renal failure—Etoposide—muscle cancer	4.51e-05	0.00127	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Etoposide—muscle cancer	4.49e-05	0.00127	CcSEcCtD
Doxorubicin—Alopecia—Vincristine—muscle cancer	4.49e-05	0.00127	CcSEcCtD
Doxorubicin—Coma—Methotrexate—muscle cancer	4.49e-05	0.00127	CcSEcCtD
Doxorubicin—TOP2A—Vinorelbine—Vincristine—muscle cancer	4.48e-05	0.0377	CbGdCrCtD
Doxorubicin—TOP2A—Podofilox—Etoposide—muscle cancer	4.47e-05	0.0377	CbGdCrCtD
Doxorubicin—TOP2A—Teniposide—Etoposide—muscle cancer	4.47e-05	0.0377	CbGdCrCtD
Doxorubicin—Stomatitis—Etoposide—muscle cancer	4.47e-05	0.00126	CcSEcCtD
Doxorubicin—Jaundice—Etoposide—muscle cancer	4.47e-05	0.00126	CcSEcCtD
Doxorubicin—NOS2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	4.47e-05	0.00184	CbGpPWpGaD
Doxorubicin—Malaise—Dactinomycin—muscle cancer	4.46e-05	0.00126	CcSEcCtD
Doxorubicin—Mental disorder—Vincristine—muscle cancer	4.45e-05	0.00126	CcSEcCtD
Doxorubicin—Neoplasm—Methotrexate—muscle cancer	4.44e-05	0.00125	CcSEcCtD
Doxorubicin—Ecchymosis—Methotrexate—muscle cancer	4.44e-05	0.00125	CcSEcCtD
Doxorubicin—Bladder pain—Methotrexate—muscle cancer	4.44e-05	0.00125	CcSEcCtD
Doxorubicin—Mouth ulceration—Methotrexate—muscle cancer	4.44e-05	0.00125	CcSEcCtD
Doxorubicin—Leukopenia—Dactinomycin—muscle cancer	4.43e-05	0.00125	CcSEcCtD
Doxorubicin—NOS1—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	4.42e-05	0.00182	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—FH—muscle cancer	4.39e-05	0.00181	CbGpPWpGaD
Doxorubicin—CYP2B6—testis—muscle cancer	4.38e-05	0.00166	CbGeAlD
Doxorubicin—Pulmonary oedema—Methotrexate—muscle cancer	4.37e-05	0.00123	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Etoposide—muscle cancer	4.34e-05	0.00122	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—KIDINS220—muscle cancer	4.32e-05	0.00178	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—ANGPT2—muscle cancer	4.29e-05	0.00177	CbGpPWpGaD
Doxorubicin—Agranulocytosis—Etoposide—muscle cancer	4.28e-05	0.00121	CcSEcCtD
Doxorubicin—Back pain—Vincristine—muscle cancer	4.28e-05	0.00121	CcSEcCtD
Doxorubicin—Sepsis—Methotrexate—muscle cancer	4.26e-05	0.0012	CcSEcCtD
Doxorubicin—TOP2A—Gastric Cancer Network 2—TP53—muscle cancer	4.22e-05	0.00174	CbGpPWpGaD
Doxorubicin—Myalgia—Dactinomycin—muscle cancer	4.21e-05	0.00119	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—CDKN2A—muscle cancer	4.18e-05	0.00173	CbGpPWpGaD
Doxorubicin—Lymphadenopathy—Methotrexate—muscle cancer	4.18e-05	0.00118	CcSEcCtD
Doxorubicin—Discomfort—Dactinomycin—muscle cancer	4.16e-05	0.00118	CcSEcCtD
Doxorubicin—Thrombophlebitis—Methotrexate—muscle cancer	4.12e-05	0.00116	CcSEcCtD
Doxorubicin—CBR1—Metabolism—FH—muscle cancer	4.1e-05	0.00169	CbGpPWpGaD
Doxorubicin—Diabetes mellitus—Methotrexate—muscle cancer	4.1e-05	0.00116	CcSEcCtD
Doxorubicin—Hypoaesthesia—Etoposide—muscle cancer	4.09e-05	0.00116	CcSEcCtD
Doxorubicin—Anaemia—Vincristine—muscle cancer	4.09e-05	0.00115	CcSEcCtD
Doxorubicin—Urinary tract disorder—Etoposide—muscle cancer	4.06e-05	0.00115	CcSEcCtD
Doxorubicin—Agitation—Vincristine—muscle cancer	4.06e-05	0.00115	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—MDM2—muscle cancer	4.06e-05	0.00167	CbGpPWpGaD
Doxorubicin—Photosensitivity—Methotrexate—muscle cancer	4.06e-05	0.00115	CcSEcCtD
Doxorubicin—Oedema—Dactinomycin—muscle cancer	4.04e-05	0.00114	CcSEcCtD
Doxorubicin—Urethral disorder—Etoposide—muscle cancer	4.03e-05	0.00114	CcSEcCtD
Doxorubicin—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	4.01e-05	0.00166	CbGpPWpGaD
Doxorubicin—Infection—Dactinomycin—muscle cancer	4.01e-05	0.00113	CcSEcCtD
Doxorubicin—Vertigo—Vincristine—muscle cancer	3.97e-05	0.00112	CcSEcCtD
Doxorubicin—Hepatic failure—Methotrexate—muscle cancer	3.97e-05	0.00112	CcSEcCtD
Doxorubicin—Leukopenia—Vincristine—muscle cancer	3.96e-05	0.00112	CcSEcCtD
Doxorubicin—Thrombocytopenia—Dactinomycin—muscle cancer	3.96e-05	0.00112	CcSEcCtD
Doxorubicin—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	3.95e-05	0.00163	CbGpPWpGaD
Doxorubicin—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	3.94e-05	0.00162	CbGpPWpGaD
Doxorubicin—AURKA—Integrated Breast Cancer Pathway—MDM2—muscle cancer	3.91e-05	0.00161	CbGpPWpGaD
Doxorubicin—Erythema multiforme—Etoposide—muscle cancer	3.89e-05	0.0011	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3.88e-05	0.0016	CbGpPWpGaD
Doxorubicin—NOS1—Alzheimers Disease—TP53—muscle cancer	3.88e-05	0.0016	CbGpPWpGaD
Doxorubicin—Renal failure acute—Methotrexate—muscle cancer	3.86e-05	0.00109	CcSEcCtD
Doxorubicin—Anorexia—Dactinomycin—muscle cancer	3.85e-05	0.00109	CcSEcCtD
Doxorubicin—XDH—Selenium Micronutrient Network—PTGS2—muscle cancer	3.85e-05	0.00159	CbGpPWpGaD
Doxorubicin—NOS3—SHP2 signaling—VEGFA—muscle cancer	3.85e-05	0.00159	CbGpPWpGaD
Doxorubicin—Eye disorder—Etoposide—muscle cancer	3.85e-05	0.00109	CcSEcCtD
Doxorubicin—Convulsion—Vincristine—muscle cancer	3.83e-05	0.00108	CcSEcCtD
Doxorubicin—Flushing—Etoposide—muscle cancer	3.82e-05	0.00108	CcSEcCtD
Doxorubicin—Cardiac disorder—Etoposide—muscle cancer	3.82e-05	0.00108	CcSEcCtD
Doxorubicin—Hypertension—Vincristine—muscle cancer	3.82e-05	0.00108	CcSEcCtD
Doxorubicin—Dermatitis exfoliative—Methotrexate—muscle cancer	3.78e-05	0.00107	CcSEcCtD
Doxorubicin—Myalgia—Vincristine—muscle cancer	3.77e-05	0.00106	CcSEcCtD
Doxorubicin—Angiopathy—Etoposide—muscle cancer	3.73e-05	0.00105	CcSEcCtD
Doxorubicin—Immune system disorder—Etoposide—muscle cancer	3.72e-05	0.00105	CcSEcCtD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	3.71e-05	0.00153	CbGpPWpGaD
Doxorubicin—Mediastinal disorder—Etoposide—muscle cancer	3.71e-05	0.00105	CcSEcCtD
Doxorubicin—Chills—Etoposide—muscle cancer	3.69e-05	0.00104	CcSEcCtD
Doxorubicin—Anaphylactoid reaction—Methotrexate—muscle cancer	3.68e-05	0.00104	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Dactinomycin—muscle cancer	3.68e-05	0.00104	CcSEcCtD
Doxorubicin—Alopecia—Etoposide—muscle cancer	3.64e-05	0.00103	CcSEcCtD
Doxorubicin—Cerebrovascular accident—Methotrexate—muscle cancer	3.64e-05	0.00103	CcSEcCtD
Doxorubicin—Lethargy—Methotrexate—muscle cancer	3.64e-05	0.00103	CcSEcCtD
Doxorubicin—ABCB1—renal system—muscle cancer	3.62e-05	0.00137	CbGeAlD
Doxorubicin—Oedema—Vincristine—muscle cancer	3.61e-05	0.00102	CcSEcCtD
Doxorubicin—Anaphylactic shock—Vincristine—muscle cancer	3.61e-05	0.00102	CcSEcCtD
Doxorubicin—CYP1B1—Tryptophan metabolism—MDM2—muscle cancer	3.59e-05	0.00148	CbGpPWpGaD
Doxorubicin—Infection—Vincristine—muscle cancer	3.59e-05	0.00101	CcSEcCtD
Doxorubicin—Osteoarthritis—Methotrexate—muscle cancer	3.56e-05	0.00101	CcSEcCtD
Doxorubicin—NOS2—Spinal Cord Injury—PTGS2—muscle cancer	3.56e-05	0.00147	CbGpPWpGaD
Doxorubicin—ABCC3—Fluoropyrimidine Activity—TP53—muscle cancer	3.55e-05	0.00146	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle, Mitotic—BUB1B—muscle cancer	3.54e-05	0.00146	CbGpPWpGaD
Doxorubicin—Nervous system disorder—Vincristine—muscle cancer	3.54e-05	0.000999	CcSEcCtD
Doxorubicin—Thrombocytopenia—Vincristine—muscle cancer	3.53e-05	0.000998	CcSEcCtD
Doxorubicin—Decreased appetite—Dactinomycin—muscle cancer	3.51e-05	0.000991	CcSEcCtD
Doxorubicin—Dysgeusia—Etoposide—muscle cancer	3.51e-05	0.00099	CcSEcCtD
Doxorubicin—Hyperhidrosis—Vincristine—muscle cancer	3.49e-05	0.000985	CcSEcCtD
Doxorubicin—Fatigue—Dactinomycin—muscle cancer	3.48e-05	0.000983	CcSEcCtD
Doxorubicin—Back pain—Etoposide—muscle cancer	3.47e-05	0.000978	CcSEcCtD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	3.46e-05	0.00143	CbGpPWpGaD
Doxorubicin—Pain—Dactinomycin—muscle cancer	3.45e-05	0.000975	CcSEcCtD
Doxorubicin—Muscle spasms—Etoposide—muscle cancer	3.44e-05	0.000972	CcSEcCtD
Doxorubicin—Anorexia—Vincristine—muscle cancer	3.44e-05	0.000971	CcSEcCtD
Doxorubicin—NOS3—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	3.39e-05	0.0014	CbGpPWpGaD
Doxorubicin—Mood swings—Methotrexate—muscle cancer	3.38e-05	0.000953	CcSEcCtD
Doxorubicin—Hypotension—Vincristine—muscle cancer	3.37e-05	0.000952	CcSEcCtD
Doxorubicin—CYP2D6—head—muscle cancer	3.37e-05	0.00128	CbGeAlD
Doxorubicin—Ataxia—Methotrexate—muscle cancer	3.35e-05	0.000946	CcSEcCtD
Doxorubicin—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	3.35e-05	0.00138	CbGpPWpGaD
Doxorubicin—NOS2—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	3.34e-05	0.00137	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—ANGPT2—muscle cancer	3.33e-05	0.00137	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Dactinomycin—muscle cancer	3.33e-05	0.00094	CcSEcCtD
Doxorubicin—Ill-defined disorder—Etoposide—muscle cancer	3.32e-05	0.000938	CcSEcCtD
Doxorubicin—Anaemia—Etoposide—muscle cancer	3.31e-05	0.000935	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Dactinomycin—muscle cancer	3.3e-05	0.000933	CcSEcCtD
Doxorubicin—Liver function test abnormal—Methotrexate—muscle cancer	3.29e-05	0.000929	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Vincristine—muscle cancer	3.29e-05	0.000928	CcSEcCtD
Doxorubicin—Insomnia—Vincristine—muscle cancer	3.26e-05	0.000922	CcSEcCtD
Doxorubicin—CYP2D6—testis—muscle cancer	3.26e-05	0.00123	CbGeAlD
Doxorubicin—Paraesthesia—Vincristine—muscle cancer	3.24e-05	0.000915	CcSEcCtD
Doxorubicin—CYP1B1—Arachidonic acid metabolism—PTGS2—muscle cancer	3.24e-05	0.00134	CbGpPWpGaD
Doxorubicin—Malaise—Etoposide—muscle cancer	3.23e-05	0.000912	CcSEcCtD
Doxorubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	3.22e-05	0.00133	CbGpPWpGaD
Doxorubicin—Breast disorder—Methotrexate—muscle cancer	3.22e-05	0.000909	CcSEcCtD
Doxorubicin—Vertigo—Etoposide—muscle cancer	3.22e-05	0.000909	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Methotrexate—muscle cancer	3.21e-05	0.000906	CcSEcCtD
Doxorubicin—Leukopenia—Etoposide—muscle cancer	3.21e-05	0.000905	CcSEcCtD
Doxorubicin—Abdominal pain—Dactinomycin—muscle cancer	3.19e-05	0.000902	CcSEcCtD
Doxorubicin—Body temperature increased—Dactinomycin—muscle cancer	3.19e-05	0.000902	CcSEcCtD
Doxorubicin—AURKA—Cell Cycle—BUB1B—muscle cancer	3.17e-05	0.00131	CbGpPWpGaD
Doxorubicin—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	3.16e-05	0.0013	CbGpPWpGaD
Doxorubicin—Loss of consciousness—Etoposide—muscle cancer	3.15e-05	0.000889	CcSEcCtD
Doxorubicin—Decreased appetite—Vincristine—muscle cancer	3.14e-05	0.000886	CcSEcCtD
Doxorubicin—Cough—Etoposide—muscle cancer	3.13e-05	0.000883	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Vincristine—muscle cancer	3.12e-05	0.00088	CcSEcCtD
Doxorubicin—Fatigue—Vincristine—muscle cancer	3.11e-05	0.000878	CcSEcCtD
Doxorubicin—NDUFS3—Metabolism—MED12—muscle cancer	3.11e-05	0.00128	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—MED12—muscle cancer	3.11e-05	0.00128	CbGpPWpGaD
Doxorubicin—Convulsion—Etoposide—muscle cancer	3.1e-05	0.000876	CcSEcCtD
Doxorubicin—Hypertension—Etoposide—muscle cancer	3.09e-05	0.000873	CcSEcCtD
Doxorubicin—Constipation—Vincristine—muscle cancer	3.09e-05	0.000871	CcSEcCtD
Doxorubicin—Pain—Vincristine—muscle cancer	3.09e-05	0.000871	CcSEcCtD
Doxorubicin—Asthma—Methotrexate—muscle cancer	3.08e-05	0.000869	CcSEcCtD
Doxorubicin—TOP2A—Vinblastine—Vincristine—muscle cancer	3.08e-05	0.0259	CbGdCrCtD
Doxorubicin—Chest pain—Etoposide—muscle cancer	3.05e-05	0.000861	CcSEcCtD
Doxorubicin—Eosinophilia—Methotrexate—muscle cancer	3.05e-05	0.000861	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	3.03e-05	0.000855	CcSEcCtD
Doxorubicin—Pancreatitis—Methotrexate—muscle cancer	3.02e-05	0.000852	CcSEcCtD
Doxorubicin—Discomfort—Etoposide—muscle cancer	3.01e-05	0.000851	CcSEcCtD
Doxorubicin—Hypersensitivity—Dactinomycin—muscle cancer	2.98e-05	0.00084	CcSEcCtD
Doxorubicin—AURKA—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	2.97e-05	0.00123	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Vincristine—muscle cancer	2.95e-05	0.000833	CcSEcCtD
Doxorubicin—Confusional state—Etoposide—muscle cancer	2.95e-05	0.000832	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.93e-05	0.00121	CbGpPWpGaD
Doxorubicin—Pancytopenia—Methotrexate—muscle cancer	2.92e-05	0.000826	CcSEcCtD
Doxorubicin—Anaphylactic shock—Etoposide—muscle cancer	2.92e-05	0.000825	CcSEcCtD
Doxorubicin—NDUFS2—Metabolism—MED12—muscle cancer	2.92e-05	0.0012	CbGpPWpGaD
Doxorubicin—Infection—Etoposide—muscle cancer	2.9e-05	0.00082	CcSEcCtD
Doxorubicin—Asthenia—Dactinomycin—muscle cancer	2.9e-05	0.000818	CcSEcCtD
Doxorubicin—Dysuria—Methotrexate—muscle cancer	2.88e-05	0.000813	CcSEcCtD
Doxorubicin—Neutropenia—Methotrexate—muscle cancer	2.88e-05	0.000813	CcSEcCtD
Doxorubicin—Thrombocytopenia—Etoposide—muscle cancer	2.86e-05	0.000808	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Methotrexate—muscle cancer	2.86e-05	0.000808	CcSEcCtD
Doxorubicin—Tachycardia—Etoposide—muscle cancer	2.85e-05	0.000806	CcSEcCtD
Doxorubicin—Abdominal pain—Vincristine—muscle cancer	2.85e-05	0.000805	CcSEcCtD
Doxorubicin—Body temperature increased—Vincristine—muscle cancer	2.85e-05	0.000805	CcSEcCtD
Doxorubicin—Skin disorder—Etoposide—muscle cancer	2.84e-05	0.000802	CcSEcCtD
Doxorubicin—NDUFS7—Metabolism—ENO2—muscle cancer	2.83e-05	0.00117	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—ENO2—muscle cancer	2.83e-05	0.00117	CbGpPWpGaD
Doxorubicin—Hyperhidrosis—Etoposide—muscle cancer	2.83e-05	0.000798	CcSEcCtD
Doxorubicin—NOS1—Spinal Cord Injury—TP53—muscle cancer	2.81e-05	0.00116	CbGpPWpGaD
Doxorubicin—Photosensitivity reaction—Methotrexate—muscle cancer	2.81e-05	0.000794	CcSEcCtD
Doxorubicin—Anorexia—Etoposide—muscle cancer	2.79e-05	0.000787	CcSEcCtD
Doxorubicin—NOS1—Hemostasis—IGF2—muscle cancer	2.77e-05	0.00114	CbGpPWpGaD
Doxorubicin—Diarrhoea—Dactinomycin—muscle cancer	2.76e-05	0.00078	CcSEcCtD
Doxorubicin—Pneumonia—Methotrexate—muscle cancer	2.76e-05	0.00078	CcSEcCtD
Doxorubicin—Drowsiness—Methotrexate—muscle cancer	2.75e-05	0.000775	CcSEcCtD
Doxorubicin—Infestation—Methotrexate—muscle cancer	2.75e-05	0.000775	CcSEcCtD
Doxorubicin—Infestation NOS—Methotrexate—muscle cancer	2.75e-05	0.000775	CcSEcCtD
Doxorubicin—ABCB1—bone marrow—muscle cancer	2.74e-05	0.00104	CbGeAlD
Doxorubicin—Hypotension—Etoposide—muscle cancer	2.73e-05	0.000771	CcSEcCtD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	2.73e-05	0.00112	CbGpPWpGaD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—muscle cancer	2.72e-05	0.000769	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—muscle cancer	2.7e-05	0.000762	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—BUB1B—muscle cancer	2.68e-05	0.00111	CbGpPWpGaD
Doxorubicin—Stomatitis—Methotrexate—muscle cancer	2.68e-05	0.000756	CcSEcCtD
Doxorubicin—Conjunctivitis—Methotrexate—muscle cancer	2.67e-05	0.000754	CcSEcCtD
Doxorubicin—NDUFS2—Metabolism—ENO2—muscle cancer	2.66e-05	0.0011	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Vincristine—muscle cancer	2.66e-05	0.000751	CcSEcCtD
Doxorubicin—Sweating—Methotrexate—muscle cancer	2.63e-05	0.000743	CcSEcCtD
Doxorubicin—Paraesthesia—Etoposide—muscle cancer	2.63e-05	0.000741	CcSEcCtD
Doxorubicin—ABCB1—vagina—muscle cancer	2.62e-05	0.000993	CbGeAlD
Doxorubicin—Haematuria—Methotrexate—muscle cancer	2.62e-05	0.000739	CcSEcCtD
Doxorubicin—Dyspnoea—Etoposide—muscle cancer	2.61e-05	0.000736	CcSEcCtD
Doxorubicin—Somnolence—Etoposide—muscle cancer	2.6e-05	0.000734	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—muscle cancer	2.6e-05	0.000733	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—muscle cancer	2.59e-05	0.000731	CcSEcCtD
Doxorubicin—Asthenia—Vincristine—muscle cancer	2.59e-05	0.000731	CcSEcCtD
Doxorubicin—Vomiting—Dactinomycin—muscle cancer	2.57e-05	0.000725	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—muscle cancer	2.56e-05	0.000723	CcSEcCtD
Doxorubicin—Rash—Dactinomycin—muscle cancer	2.55e-05	0.000719	CcSEcCtD
Doxorubicin—Decreased appetite—Etoposide—muscle cancer	2.54e-05	0.000718	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Etoposide—muscle cancer	2.52e-05	0.000713	CcSEcCtD
Doxorubicin—Fatigue—Etoposide—muscle cancer	2.52e-05	0.000712	CcSEcCtD
Doxorubicin—Pain—Etoposide—muscle cancer	2.5e-05	0.000706	CcSEcCtD
Doxorubicin—Constipation—Etoposide—muscle cancer	2.5e-05	0.000706	CcSEcCtD
Doxorubicin—DHCR7—Metabolism—MED12—muscle cancer	2.48e-05	0.00102	CbGpPWpGaD
Doxorubicin—Haemoglobin—Methotrexate—muscle cancer	2.48e-05	0.000699	CcSEcCtD
Doxorubicin—Diarrhoea—Vincristine—muscle cancer	2.47e-05	0.000697	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—muscle cancer	2.47e-05	0.000696	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—muscle cancer	2.47e-05	0.000696	CcSEcCtD
Doxorubicin—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	2.45e-05	0.00101	CbGpPWpGaD
Doxorubicin—Pharyngitis—Methotrexate—muscle cancer	2.45e-05	0.000691	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—muscle cancer	2.43e-05	0.000687	CcSEcCtD
Doxorubicin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	2.43e-05	0.001	CbGpPWpGaD
Doxorubicin—ABCB1—head—muscle cancer	2.42e-05	0.000918	CbGeAlD
Doxorubicin—Urethral disorder—Methotrexate—muscle cancer	2.42e-05	0.000682	CcSEcCtD
Doxorubicin—Feeling abnormal—Etoposide—muscle cancer	2.41e-05	0.00068	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—BUB1B—muscle cancer	2.4e-05	0.000989	CbGpPWpGaD
Doxorubicin—Nausea—Dactinomycin—muscle cancer	2.4e-05	0.000677	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—KIDINS220—muscle cancer	2.39e-05	0.000987	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—FH—muscle cancer	2.39e-05	0.000986	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Etoposide—muscle cancer	2.39e-05	0.000675	CcSEcCtD
Doxorubicin—Dizziness—Vincristine—muscle cancer	2.39e-05	0.000674	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—muscle cancer	2.38e-05	0.000671	CcSEcCtD
Doxorubicin—NOS3—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	2.36e-05	0.000972	CbGpPWpGaD
Doxorubicin—ABCB1—testis—muscle cancer	2.34e-05	0.000886	CbGeAlD
Doxorubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	2.34e-05	0.000964	CbGpPWpGaD
Doxorubicin—Erythema multiforme—Methotrexate—muscle cancer	2.33e-05	0.000658	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—TP53—muscle cancer	2.33e-05	0.00096	CbGpPWpGaD
Doxorubicin—Urticaria—Etoposide—muscle cancer	2.32e-05	0.000656	CcSEcCtD
Doxorubicin—CBR1—Metabolism—MED12—muscle cancer	2.32e-05	0.000955	CbGpPWpGaD
Doxorubicin—Body temperature increased—Etoposide—muscle cancer	2.31e-05	0.000653	CcSEcCtD
Doxorubicin—Abdominal pain—Etoposide—muscle cancer	2.31e-05	0.000653	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—FH—muscle cancer	2.31e-05	0.000952	CbGpPWpGaD
Doxorubicin—Eye disorder—Methotrexate—muscle cancer	2.3e-05	0.00065	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—muscle cancer	2.3e-05	0.000649	CcSEcCtD
Doxorubicin—Vomiting—Vincristine—muscle cancer	2.3e-05	0.000648	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—muscle cancer	2.29e-05	0.000646	CcSEcCtD
Doxorubicin—Rash—Vincristine—muscle cancer	2.28e-05	0.000642	CcSEcCtD
Doxorubicin—Dermatitis—Vincristine—muscle cancer	2.27e-05	0.000642	CcSEcCtD
Doxorubicin—DHCR7—Metabolism—ENO2—muscle cancer	2.26e-05	0.000933	CbGpPWpGaD
Doxorubicin—Headache—Vincristine—muscle cancer	2.26e-05	0.000638	CcSEcCtD
Doxorubicin—AURKA—Integrated Breast Cancer Pathway—TP53—muscle cancer	2.25e-05	0.000926	CbGpPWpGaD
Doxorubicin—Angiopathy—Methotrexate—muscle cancer	2.24e-05	0.000631	CcSEcCtD
Doxorubicin—Immune system disorder—Methotrexate—muscle cancer	2.23e-05	0.000629	CcSEcCtD
Doxorubicin—NOS3—Signaling by VEGF—VEGFA—muscle cancer	2.22e-05	0.000917	CbGpPWpGaD
Doxorubicin—Mediastinal disorder—Methotrexate—muscle cancer	2.22e-05	0.000627	CcSEcCtD
Doxorubicin—Chills—Methotrexate—muscle cancer	2.21e-05	0.000624	CcSEcCtD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—muscle cancer	2.19e-05	0.000905	CbGpPWpGaD
Doxorubicin—Alopecia—Methotrexate—muscle cancer	2.18e-05	0.000615	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—muscle cancer	2.16e-05	0.00061	CcSEcCtD
Doxorubicin—Hypersensitivity—Etoposide—muscle cancer	2.15e-05	0.000608	CcSEcCtD
Doxorubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	2.15e-05	0.000887	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—FH—muscle cancer	2.15e-05	0.000885	CbGpPWpGaD
Doxorubicin—Malnutrition—Methotrexate—muscle cancer	2.15e-05	0.000606	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—muscle cancer	2.15e-05	0.000606	CcSEcCtD
Doxorubicin—Nausea—Vincristine—muscle cancer	2.14e-05	0.000605	CcSEcCtD
Doxorubicin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	2.13e-05	0.00088	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—TP53—muscle cancer	2.12e-05	0.000874	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—ENO2—muscle cancer	2.11e-05	0.00087	CbGpPWpGaD
Doxorubicin—Dysgeusia—Methotrexate—muscle cancer	2.1e-05	0.000593	CcSEcCtD
Doxorubicin—Asthenia—Etoposide—muscle cancer	2.1e-05	0.000592	CcSEcCtD
Doxorubicin—NOS2—Hemostasis—IGF2—muscle cancer	2.09e-05	0.000861	CbGpPWpGaD
Doxorubicin—Back pain—Methotrexate—muscle cancer	2.08e-05	0.000586	CcSEcCtD
Doxorubicin—Pruritus—Etoposide—muscle cancer	2.07e-05	0.000584	CcSEcCtD
Doxorubicin—NOS1—Disease—ENO2—muscle cancer	2.05e-05	0.000845	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KIDINS220—muscle cancer	2.02e-05	0.000834	CbGpPWpGaD
Doxorubicin—Vision blurred—Methotrexate—muscle cancer	2.02e-05	0.000571	CcSEcCtD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.01e-05	0.000828	CbGpPWpGaD
Doxorubicin—Diarrhoea—Etoposide—muscle cancer	2e-05	0.000565	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—muscle cancer	1.99e-05	0.000562	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—muscle cancer	1.98e-05	0.00056	CcSEcCtD
Doxorubicin—NOS3—Metabolism—FH—muscle cancer	1.95e-05	0.000804	CbGpPWpGaD
Doxorubicin—Malaise—Methotrexate—muscle cancer	1.94e-05	0.000546	CcSEcCtD
Doxorubicin—Dizziness—Etoposide—muscle cancer	1.93e-05	0.000546	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—muscle cancer	1.93e-05	0.000544	CcSEcCtD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.92e-05	0.000793	CbGpPWpGaD
Doxorubicin—Leukopenia—Methotrexate—muscle cancer	1.92e-05	0.000542	CcSEcCtD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—BUB1B—muscle cancer	1.88e-05	0.000774	CbGpPWpGaD
Doxorubicin—Cough—Methotrexate—muscle cancer	1.87e-05	0.000529	CcSEcCtD
Doxorubicin—NOS1—Disease—HMGA1—muscle cancer	1.86e-05	0.000768	CbGpPWpGaD
Doxorubicin—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.86e-05	0.000767	CbGpPWpGaD
Doxorubicin—Convulsion—Methotrexate—muscle cancer	1.86e-05	0.000525	CcSEcCtD
Doxorubicin—Vomiting—Etoposide—muscle cancer	1.86e-05	0.000525	CcSEcCtD
Doxorubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	1.85e-05	0.000763	CbGpPWpGaD
Doxorubicin—Rash—Etoposide—muscle cancer	1.84e-05	0.00052	CcSEcCtD
Doxorubicin—Dermatitis—Etoposide—muscle cancer	1.84e-05	0.00052	CcSEcCtD
Doxorubicin—Headache—Etoposide—muscle cancer	1.83e-05	0.000517	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—muscle cancer	1.83e-05	0.000516	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—muscle cancer	1.83e-05	0.000516	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—muscle cancer	1.83e-05	0.000516	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	1.81e-05	0.000512	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—muscle cancer	1.81e-05	0.00051	CcSEcCtD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.77e-05	0.00073	CbGpPWpGaD
Doxorubicin—Confusional state—Methotrexate—muscle cancer	1.77e-05	0.000499	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—muscle cancer	1.75e-05	0.000494	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	1.75e-05	0.00072	CbGpPWpGaD
Doxorubicin—Infection—Methotrexate—muscle cancer	1.74e-05	0.000491	CcSEcCtD
Doxorubicin—Nausea—Etoposide—muscle cancer	1.74e-05	0.00049	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.72e-05	0.000709	CbGpPWpGaD
Doxorubicin—Nervous system disorder—Methotrexate—muscle cancer	1.72e-05	0.000485	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—muscle cancer	1.71e-05	0.000484	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—PTCH1—muscle cancer	1.7e-05	0.000701	CbGpPWpGaD
Doxorubicin—Skin disorder—Methotrexate—muscle cancer	1.7e-05	0.00048	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—muscle cancer	1.69e-05	0.000478	CcSEcCtD
Doxorubicin—TOP2A—Cell Cycle—BUB1B—muscle cancer	1.68e-05	0.000692	CbGpPWpGaD
Doxorubicin—NOS1—Disease—FOXO4—muscle cancer	1.67e-05	0.000688	CbGpPWpGaD
Doxorubicin—Anorexia—Methotrexate—muscle cancer	1.67e-05	0.000471	CcSEcCtD
Doxorubicin—YWHAG—Apoptosis—TP53—muscle cancer	1.67e-05	0.000687	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.66e-05	0.000683	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.65e-05	0.000681	CbGpPWpGaD
Doxorubicin—Hypotension—Methotrexate—muscle cancer	1.64e-05	0.000462	CcSEcCtD
Doxorubicin—NOS3—Hemostasis—IGF2—muscle cancer	1.62e-05	0.000668	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.62e-05	0.000667	CbGpPWpGaD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—muscle cancer	1.6e-05	0.00045	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—muscle cancer	1.58e-05	0.000447	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—FH—muscle cancer	1.58e-05	0.000652	CbGpPWpGaD
Doxorubicin—Paraesthesia—Methotrexate—muscle cancer	1.57e-05	0.000444	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—muscle cancer	1.56e-05	0.000441	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—muscle cancer	1.56e-05	0.00044	CcSEcCtD
Doxorubicin—NOS2—Disease—ENO2—muscle cancer	1.55e-05	0.000637	CbGpPWpGaD
Doxorubicin—Dyspepsia—Methotrexate—muscle cancer	1.54e-05	0.000435	CcSEcCtD
Doxorubicin—Decreased appetite—Methotrexate—muscle cancer	1.52e-05	0.00043	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—FH—muscle cancer	1.52e-05	0.000625	CbGpPWpGaD
Doxorubicin—Gastrointestinal disorder—Methotrexate—muscle cancer	1.51e-05	0.000427	CcSEcCtD
Doxorubicin—Fatigue—Methotrexate—muscle cancer	1.51e-05	0.000426	CcSEcCtD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.51e-05	0.000622	CbGpPWpGaD
Doxorubicin—Pain—Methotrexate—muscle cancer	1.5e-05	0.000423	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—FOXO4—muscle cancer	1.46e-05	0.000603	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.46e-05	0.000601	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—CDKN2A—muscle cancer	1.45e-05	0.000597	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Methotrexate—muscle cancer	1.44e-05	0.000407	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—CNR1—muscle cancer	1.44e-05	0.000592	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Methotrexate—muscle cancer	1.43e-05	0.000404	CcSEcCtD
Doxorubicin—AKR1C3—Disease—ENO2—muscle cancer	1.42e-05	0.000585	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HMGA1—muscle cancer	1.4e-05	0.000579	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—MDM2—muscle cancer	1.4e-05	0.000579	CbGpPWpGaD
Doxorubicin—Urticaria—Methotrexate—muscle cancer	1.39e-05	0.000393	CcSEcCtD
Doxorubicin—NOS2—Circadian rythm related genes—TP53—muscle cancer	1.38e-05	0.000571	CbGpPWpGaD
Doxorubicin—Abdominal pain—Methotrexate—muscle cancer	1.38e-05	0.000391	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—muscle cancer	1.38e-05	0.000391	CcSEcCtD
Doxorubicin—NQO1—Metabolism—MED12—muscle cancer	1.35e-05	0.000557	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.31e-05	0.000538	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—MED12—muscle cancer	1.3e-05	0.000538	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HMGA1—muscle cancer	1.29e-05	0.000532	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Methotrexate—muscle cancer	1.29e-05	0.000364	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	1.28e-05	0.000526	CbGpPWpGaD
Doxorubicin—NOS2—Disease—FOXO4—muscle cancer	1.26e-05	0.000519	CbGpPWpGaD
Doxorubicin—Asthenia—Methotrexate—muscle cancer	1.26e-05	0.000355	CcSEcCtD
Doxorubicin—Pruritus—Methotrexate—muscle cancer	1.24e-05	0.00035	CcSEcCtD
Doxorubicin—NOS1—Disease—FOXO1—muscle cancer	1.23e-05	0.000508	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—ENO2—muscle cancer	1.23e-05	0.000508	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.23e-05	0.000506	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—MED12—muscle cancer	1.21e-05	0.0005	CbGpPWpGaD
Doxorubicin—NOS3—Disease—ENO2—muscle cancer	1.2e-05	0.000495	CbGpPWpGaD
Doxorubicin—Diarrhoea—Methotrexate—muscle cancer	1.2e-05	0.000338	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—ENO2—muscle cancer	1.19e-05	0.00049	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—FH—muscle cancer	1.19e-05	0.00049	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IGF2—muscle cancer	1.17e-05	0.000484	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—VEGFA—muscle cancer	1.16e-05	0.000479	CbGpPWpGaD
Doxorubicin—Dizziness—Methotrexate—muscle cancer	1.16e-05	0.000327	CcSEcCtD
Doxorubicin—AKR1C3—Disease—FOXO4—muscle cancer	1.16e-05	0.000477	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—FH—muscle cancer	1.15e-05	0.000474	CbGpPWpGaD
Doxorubicin—Vomiting—Methotrexate—muscle cancer	1.11e-05	0.000314	CcSEcCtD
Doxorubicin—XDH—Metabolism—ENO2—muscle cancer	1.11e-05	0.000456	CbGpPWpGaD
Doxorubicin—Rash—Methotrexate—muscle cancer	1.1e-05	0.000312	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—muscle cancer	1.1e-05	0.000311	CcSEcCtD
Doxorubicin—NOS3—Metabolism—MED12—muscle cancer	1.1e-05	0.000454	CbGpPWpGaD
Doxorubicin—Headache—Methotrexate—muscle cancer	1.1e-05	0.00031	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—CDKN2A—muscle cancer	1.1e-05	0.000452	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HMGA1—muscle cancer	1.09e-05	0.00045	CbGpPWpGaD
Doxorubicin—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	1.09e-05	0.000449	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—FOXO1—muscle cancer	1.08e-05	0.000445	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—MDM2—muscle cancer	1.06e-05	0.000439	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—FH—muscle cancer	1.05e-05	0.000431	CbGpPWpGaD
Doxorubicin—Nausea—Methotrexate—muscle cancer	1.04e-05	0.000294	CcSEcCtD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.01e-05	0.000415	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—ENO2—muscle cancer	1e-05	0.000414	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—PTGS2—muscle cancer	9.86e-06	0.000407	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—PTGS2—muscle cancer	9.86e-06	0.000407	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	9.86e-06	0.000407	CbGpPWpGaD
Doxorubicin—NOS3—Disease—FOXO4—muscle cancer	9.78e-06	0.000403	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—TP53—muscle cancer	9.47e-06	0.00039	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTCH1—muscle cancer	9.43e-06	0.000389	CbGpPWpGaD
Doxorubicin—NOS1—Disease—KIT—muscle cancer	9.4e-06	0.000387	CbGpPWpGaD
Doxorubicin—NOS2—Disease—FOXO1—muscle cancer	9.3e-06	0.000384	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.3e-06	0.000383	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—PTGS2—muscle cancer	9.27e-06	0.000382	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—MED12—muscle cancer	8.94e-06	0.000369	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—TP53—muscle cancer	8.77e-06	0.000362	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—VEGFA—muscle cancer	8.76e-06	0.000361	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—VEGFA—muscle cancer	8.71e-06	0.000359	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—muscle cancer	8.58e-06	0.000354	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—MED12—muscle cancer	8.57e-06	0.000353	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—FOXO1—muscle cancer	8.55e-06	0.000352	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—KIT—muscle cancer	8.23e-06	0.000339	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ENO2—muscle cancer	8.15e-06	0.000336	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—FOXO4—muscle cancer	8.11e-06	0.000334	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—TP53—muscle cancer	8.05e-06	0.000332	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTCH1—muscle cancer	7.97e-06	0.000328	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CNR1—muscle cancer	7.96e-06	0.000328	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PTGS2—muscle cancer	7.89e-06	0.000325	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ENO2—muscle cancer	7.81e-06	0.000322	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—CDKN2A—muscle cancer	7.67e-06	0.000316	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—FH—muscle cancer	7.67e-06	0.000316	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—MDM2—muscle cancer	7.44e-06	0.000307	CbGpPWpGaD
Doxorubicin—NOS1—Disease—MDM2—muscle cancer	7.4e-06	0.000305	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PTGS2—muscle cancer	7.35e-06	0.000303	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ENO2—muscle cancer	7.31e-06	0.000301	CbGpPWpGaD
Doxorubicin—NOS3—Disease—FOXO1—muscle cancer	7.22e-06	0.000298	CbGpPWpGaD
Doxorubicin—NOS1—Disease—PTGS2—muscle cancer	7.14e-06	0.000294	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KIT—muscle cancer	7.09e-06	0.000292	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—FOXO4—muscle cancer	6.85e-06	0.000282	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—VEGFA—muscle cancer	6.8e-06	0.00028	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CNR1—muscle cancer	6.72e-06	0.000277	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—MED12—muscle cancer	6.72e-06	0.000277	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HMGA1—muscle cancer	6.65e-06	0.000274	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—TP53—muscle cancer	6.62e-06	0.000273	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KIT—muscle cancer	6.51e-06	0.000269	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IGF2—muscle cancer	6.51e-06	0.000268	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—MED12—muscle cancer	6.5e-06	0.000268	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MDM2—muscle cancer	6.48e-06	0.000267	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.37e-06	0.000263	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ENO2—muscle cancer	6.12e-06	0.000252	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.11e-06	0.000252	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—TP53—muscle cancer	6.1e-06	0.000252	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—FOXO1—muscle cancer	5.99e-06	0.000247	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—FOXO4—muscle cancer	5.96e-06	0.000246	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ENO2—muscle cancer	5.92e-06	0.000244	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—MED12—muscle cancer	5.91e-06	0.000244	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.66e-06	0.000233	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—FH—muscle cancer	5.65e-06	0.000233	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MDM2—muscle cancer	5.58e-06	0.00023	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KIT—muscle cancer	5.5e-06	0.000227	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IGF2—muscle cancer	5.5e-06	0.000227	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	5.46e-06	0.000225	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ENO2—muscle cancer	5.39e-06	0.000222	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PTGS2—muscle cancer	5.38e-06	0.000222	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—FH—muscle cancer	5.33e-06	0.00022	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TP53—muscle cancer	5.14e-06	0.000212	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MDM2—muscle cancer	5.13e-06	0.000212	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—FOXO1—muscle cancer	5.06e-06	0.000209	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTGS2—muscle cancer	4.95e-06	0.000204	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—VEGFA—muscle cancer	4.92e-06	0.000203	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.79e-06	0.000197	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.63e-06	0.000191	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KIT—muscle cancer	4.56e-06	0.000188	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—FOXO1—muscle cancer	4.4e-06	0.000181	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MDM2—muscle cancer	4.33e-06	0.000179	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—MED12—muscle cancer	4.33e-06	0.000179	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.3e-06	0.000177	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTGS2—muscle cancer	4.29e-06	0.000177	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—muscle cancer	4.27e-06	0.000176	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTGS2—muscle cancer	4.18e-06	0.000172	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—muscle cancer	4.14e-06	0.000171	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ENO2—muscle cancer	3.95e-06	0.000163	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KIT—muscle cancer	3.85e-06	0.000159	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—muscle cancer	3.85e-06	0.000159	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—muscle cancer	3.72e-06	0.000153	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MDM2—muscle cancer	3.59e-06	0.000148	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—muscle cancer	3.5e-06	0.000144	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—FH—muscle cancer	3.48e-06	0.000144	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KIT—muscle cancer	3.35e-06	0.000138	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.25e-06	0.000134	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—MED12—muscle cancer	3.2e-06	0.000132	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MDM2—muscle cancer	3.04e-06	0.000125	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—MED12—muscle cancer	3.01e-06	0.000124	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ENO2—muscle cancer	2.91e-06	0.00012	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—muscle cancer	2.84e-06	0.000117	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ENO2—muscle cancer	2.75e-06	0.000113	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—muscle cancer	2.73e-06	0.000112	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—muscle cancer	2.72e-06	0.000112	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MDM2—muscle cancer	2.64e-06	0.000109	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—muscle cancer	2.55e-06	0.000105	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—muscle cancer	2.31e-06	9.5e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—muscle cancer	2.13e-06	8.79e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—muscle cancer	2.06e-06	8.5e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—muscle cancer	2.06e-06	8.5e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—MED12—muscle cancer	1.97e-06	8.12e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—muscle cancer	1.88e-06	7.74e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ENO2—muscle cancer	1.79e-06	7.4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—muscle cancer	1.74e-06	7.18e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—muscle cancer	1.38e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—muscle cancer	1.01e-06	4.18e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—muscle cancer	9.56e-07	3.94e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—muscle cancer	6.25e-07	2.58e-05	CbGpPWpGaD
